1,165 reports of this reaction
1.6% of all DOXYCLYCLINE HYCLATE reports
#11 most reported adverse reaction
DYSPNOEA is the #11 most commonly reported adverse reaction for DOXYCLYCLINE HYCLATE, manufactured by Lupin Pharmaceuticals, Inc.. There are 1,165 FDA adverse event reports linking DOXYCLYCLINE HYCLATE to DYSPNOEA. This represents approximately 1.6% of all 70,851 adverse event reports for this drug.
Patients taking DOXYCLYCLINE HYCLATE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for DOXYCLYCLINE HYCLATE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for DOXYCLYCLINE HYCLATE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 1,165 FDA reports for DOXYCLYCLINE HYCLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 1.6% of all adverse event reports for DOXYCLYCLINE HYCLATE, making it a notable side effect.
If you experience dyspnoea while taking DOXYCLYCLINE HYCLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.